Hypophosphatemic rickets: effect of 1 alpha, 25-dihydroxyvitamin D3 on growth and mineral metabolism.

Abstract

Growth retardation nearly invariably accompanies hypophosphatemic rickets. Studies were conducted in an adolescent male with this disorder as follows. Protocol I: age, 6 to 16 years; treatment per day, 5,000 to 80,000 units vitamin D2, 1,760 to 2,200 mg phosphorus, orally as buffered phosphate; growth velocity, 5 to 6 cm/year. Protocol II: age 16 to 17 years; treatment per day, 1 alpha,25-dihydroxyvitamin D3, 1 microgram; 2,200 mg of phosphorus, orally as buffered phosphate; growth velocity, 14 cm/year. The height improved from less than third percentile for the decade during study protocol I to the 25th percentile during protocol II. Mineral balance studies showed a reduction of urinary and stool phosphorus during treatment protocol II, while the patient was receiving metabolic diet. The serum phosphorus improved from 2.2 to 4.3 mg/dl and radiologic healing of rickets was documented. No hypercalcemic episode was encountered. The data support the contention that 1 alpha,25-dihydroxyvitamin D3 is the treatment of choice for hypophosphatemic rickets.

• Authors: J C Chan, F C Bartter
• Journal: Pediatrics (Pediatrics) Vol. 64 Issue 4 Pg. 488-95 (Oct 1979) ISSN: 0031-4005 [Print] United States
• PMID: 492815 (Publication Type: Case Reports, Journal Article)

Chemical References

• Dihydroxycholecalciferols
• Hydroxycholecalciferols
• Minerals
• Phosphates
• Phosphorus
• Calcium

Topics

• Adolescent
• Body Height (drug effects)
• Calcium (metabolism)
• Child
• Dihydroxycholecalciferols (pharmacology, therapeutic use)
• Growth (drug effects)
• Humans
• Hydroxycholecalciferols (therapeutic use)
• Male
• Minerals (metabolism)
• Phosphates (blood)
• Phosphorus (metabolism)
• Radiography
• Rickets (diagnostic imaging, drug therapy, metabolism)